Inclisiran : new era of lipid-lowering therapy?

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F23%3A00083846" target="_blank" >RIV/00023001:_____/23:00083846 - isvavai.cz</a>

Výsledek na webu

<a href="https://www.e-coretvasa.cz/pdfs/cor/2023/01/09.pdf" target="_blank" >https://www.e-coretvasa.cz/pdfs/cor/2023/01/09.pdf</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.33678/cor.2022.043" target="_blank" >10.33678/cor.2022.043</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Inclisiran : new era of lipid-lowering therapy?

Popis výsledku v původním jazyce

Dyslipidemia is the most frequent metabolic abnormality in western world population and a major risk factor for coronary artery disease (CAD) development. Dyslipidemia treatment is still insufficient and achieving target LDL-level infrequent. Statins are a cornerstone of dyslipidemia management. Although statins are one of the safest drugs on the market, statin therapy can be associated with muscle symptoms and increased risk of DM development. Statin discontinuation is frequent, often driven by negative media coverage. Inclisiran is a therapeutic oligonucleotide that employs RNA interference and inhibits the translation of PCSK9-mRNA leading to long-lasting LDL-cholesterol lowering. LDL-cholesterol-lowering effect of inclisiran is reversed at the rate of approximately 2% per month, so the effect of a single dose persists up to approximately two years. When administered once every six months, inclisiran therapy decreases the level circulating LDL-cholesterol by 50–55% and up to 65% in selected patient populations. Inclisiran therapy is not associated with alterations in platelet count, blood lymphocyte, monocyte or neutrophil count, does not cause alterations in blood TNF-alpha or IL-6 concentrations and does not induce relevant anti-drug antibodies. The only relevant side effect is an adverse reaction at the injection site. Inclisiran thus has the potential to become widely prescribed drug that will greatly contribute to dyslipidemia management and further decrease of CAD incidence. © 2023, ČKS.

Název v anglickém jazyce

Inclisiran : new era of lipid-lowering therapy?

Popis výsledku anglicky

Dyslipidemia is the most frequent metabolic abnormality in western world population and a major risk factor for coronary artery disease (CAD) development. Dyslipidemia treatment is still insufficient and achieving target LDL-level infrequent. Statins are a cornerstone of dyslipidemia management. Although statins are one of the safest drugs on the market, statin therapy can be associated with muscle symptoms and increased risk of DM development. Statin discontinuation is frequent, often driven by negative media coverage. Inclisiran is a therapeutic oligonucleotide that employs RNA interference and inhibits the translation of PCSK9-mRNA leading to long-lasting LDL-cholesterol lowering. LDL-cholesterol-lowering effect of inclisiran is reversed at the rate of approximately 2% per month, so the effect of a single dose persists up to approximately two years. When administered once every six months, inclisiran therapy decreases the level circulating LDL-cholesterol by 50–55% and up to 65% in selected patient populations. Inclisiran therapy is not associated with alterations in platelet count, blood lymphocyte, monocyte or neutrophil count, does not cause alterations in blood TNF-alpha or IL-6 concentrations and does not induce relevant anti-drug antibodies. The only relevant side effect is an adverse reaction at the injection site. Inclisiran thus has the potential to become widely prescribed drug that will greatly contribute to dyslipidemia management and further decrease of CAD incidence. © 2023, ČKS.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30201 - Cardiac and Cardiovascular systems

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2023

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Cor et vasa

ISSN

0010-8650

e-ISSN

1803-7712

Svazek periodika

65

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

CZ - Česká republika

Počet stran výsledku

7

Strana od-do

69-75

Kód UT WoS článku

000959862100009

EID výsledku v databázi Scopus

2-s2.0-85151274363